Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Takeda Says It Does Not Plan To Advance TAK-861 In Narcolepsy Type 2 At This Time; Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolepsy Type 1 Rapidly In H1 Of Its FY24

Author: Benzinga Newsdesk | February 08, 2024 07:05pm

Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024.

Posted In: TAK